Cisplatin

Generic Name: Cisplatin

Brand Names: Platinol

Drug Type: Small Molecule

Chemical Formula: Cl_₂H_₆N_₂Pt

CAS Number: 15663-27-1

Unique Ingredient Identifier: Q20Q21Q62J

Background: Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Indication: For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Associated Conditions: Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer

Clinical Trials

Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal Carcinoma

Phase 2

Not yet recruiting

Conditions: Metastatic Nasopharyngeal Carcinoma
Intermittent Systematic Chemotherapy

Interventions: Drug: Gemcitabine
Drug: Cisplatin
Drug: Paclitaxel protein-bound
Drug: Capecitabine
Drug: Tislelizumab

First Posted Date: 2024-03-26

Last Posted Date: 2024-03-26

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 39

Registration Number: NCT06331845

Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Clinically Node-negative Head and Neck Squamous Cell Carcinoma

Phase 2

Recruiting

Conditions: Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Tislelizumab（neoadjuvant）
Drug: Cisplatin （neoadjuvant）
Drug: Nab-paclitaxel （neoadjuvant）
Procedure: Surgical resection
Drug: Cisplatin（adjuvant）
Drug: Tislelizumab（adjuvant）
Radiation: Radiation
Drug: Carboplatin（neoadjuvant）
Drug: Carboplatin（adjuvant）

First Posted Date: 2024-03-21

Last Posted Date: 2024-05-17

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 154

Registration Number: NCT06323369

Locations: 🇨🇳
Medical Ethics Committee of Sun Yat-sen Memorial Hospital, Guangzhou, Yuexiu, China

SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma

Phase 2

Recruiting

Conditions: Nasopharyngeal Carcinoma

Interventions: Radiation: SBRT
Radiation: Low-dose Radiotherapy (LDRT)
Drug: Toripalimab
Drug: Gemcitabine
Drug: Cisplatin
Radiation: IMRT

First Posted Date: 2024-03-21

Last Posted Date: 2024-08-20

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 148

Registration Number: NCT06323239

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer

Phase 2

Recruiting

Conditions: Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC V8
Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC V8
Oropharyngeal Squamous Cell Carcinoma

Interventions: Procedure: Biospecimen Collection
Drug: Carboplatin
Drug: Cisplatin
Procedure: Computed Tomography
Radiation: External Beam Radiation Therapy
Drug: Paclitaxel
Procedure: Positron Emission Tomography
Other: Questionnaire Administration

First Posted Date: 2024-03-21

Last Posted Date: 2025-02-14

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Target Recruit Count: 45

Registration Number: NCT06323460

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

Phase 3

Recruiting

Conditions: Non Small Cell Lung Cancer

Interventions: Biological: Sacituzumab tirumotecan
Biological: Pembrolizumab
Drug: Cisplatin
Drug: Rescue medication
Drug: Pemetrexed
Drug: Gemcitabine
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2024-03-15

Last Posted Date: 2025-05-11

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 780

Registration Number: NCT06312137

Locations: 🇺🇸
Indiana University Health Arnett Cancer Center ( Site 0076), Lafayette, Indiana, United States
🇺🇸
Saint Elizabeth Medical Center Edgewood-Cancer Care Center ( Site 0061), Edgewood, Kentucky, United States
🇺🇸
Mercy Research - David C. Pratt Cancer Center ( Site 0006), Saint Louis, Missouri, United States

and more 201 locations

GAMEC-II, Risk-adapted Protocol for Relapsed Germ Cell Tumours (GCT)

Phase 2

Completed

Conditions: Testicular Neoplasms

Interventions: Drug: Dactinomycin
Drug: Pegfilgrastim
Drug: Methotrexate
Drug: Etoposide
Drug: Cisplatin
Drug: Epirubicin

First Posted Date: 2024-03-13

Last Posted Date: 2024-03-13

Lead Sponsor: Queen Mary University of London

Target Recruit Count: 36

Registration Number: NCT06309732

Locations: 🇬🇧
Barts and the London NHS Trust, London, United Kingdom

Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations

Phase 2

Not yet recruiting

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Adebrelimab
Drug: paclitaxel for injection (albumin bound)
Drug: Cisplatin or Carboplatin

First Posted Date: 2024-03-07

Last Posted Date: 2024-03-07

Lead Sponsor: Liaoning Tumor Hospital & Institute

Target Recruit Count: 36

Registration Number: NCT06299371

The Efficacy of PIPAC and Minimally Invasive Radical Resection in High-risk Gastric Cancer Patients.

Phase 2

Not yet recruiting

Conditions: Minimally Invasive Surgical Procedures
Chemotherapy, Adjuvant
Peritoneal Metastases
Gastric Cancer

Interventions: Drug: Cisplatin
Drug: Doxorubicin

First Posted Date: 2024-03-06

Last Posted Date: 2024-03-06

Lead Sponsor: Odense University Hospital

Target Recruit Count: 264

Registration Number: NCT06295094

Locations: 🇺🇸
City of Hope, Duarte, California, United States
🇫🇷
University Hospital Lille, Lille, France
🇩🇪
Charité, University of Berlin, Berlin, Germany

and more 2 locations

Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer

Phase 2

Not yet recruiting

Conditions: Cervical Cancer
Neoadjuvant Chemoimmunotherapy
Radical Hysterectomy
Extrafascial Hysterectomy

Interventions: Drug: Cadonilimab
Drug: Paclitaxel-albumin
Drug: Cisplatin
Procedure: Extrafascial hysterectomy
Procedure: Radical hysterectomy
Procedure: Cone biopsy

First Posted Date: 2024-03-04

Last Posted Date: 2024-03-04

Lead Sponsor: Tongji Hospital

Target Recruit Count: 50

Registration Number: NCT06289751

Locations: 🇨🇳
Qilu Hospital of Shandong University, Jinan, Shandong, China
🇨🇳
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer

Phase 2

Recruiting

Conditions: Cervical Cancer
Neoadjuvant Chemoimmunotherapy
Fertility Preservation

Interventions: Drug: Camrelizumab
Drug: Cisplatin
Drug: Nab paclitaxel
Procedure: biopsy

First Posted Date: 2024-03-01

Last Posted Date: 2024-11-05

Lead Sponsor: Tongji Hospital

Target Recruit Count: 40

Registration Number: NCT06289062

Locations: 🇨🇳
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China
🇨🇳
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy